As of 2025-10-25, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -6.71. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 3,240.92 mil USD. RARE's TTM EBITDA according to its financial statements is -482.91 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 13.2x | 12.8x |
| Forward P/E multiples | 15.4x - 43.4x | 29.4x |
| Fair Price | (77.17) - (66.15) | (105.73) |
| Upside | -329.5% - -296.7% | -414.4% |
| Date | EV/EBITDA |